Research
SGA Study/NESGAS (North European Small for Gestational Age Study)
Aim:
To determine the safety and efficacy of 3 different GH treatment regimens in SGA children – high dose, low dose and dose titration according to IGF-I levels.
NESGAS Extension:
The NESGAS Extension Study follows participants until they reach final height. The primary objectives are to evaluate changes in insulin sensitivity/secretion and impaired glucose tolerance. Secondary outcomes are growth, body composition and cardiovascular risk factors.
Trial status:
The Extension of the study has so far recruited a total of 56 participants from the UK, Ireland and Denmark from the original 116 participants in 4 countries.
| Documents | ||
 |
Nesgas Protocol v4 | (pdf) (767kb) |
|
Nesgas Extension Protocol v3 | (pdf) (1.39mb) |
